UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SYNAFFIX B.V.,
Petitioner,

v.

HANGZHOU DAC BIOTECH CO., LTD.,
Patent Owner.

Case No. IPR2022-01531
U.S. Patent No. 10,131,682

Patent Owner's Current Exhibit List

EXHIBIT LIST

No.	Exhibit Description	Previously submitted
2001	Declaration of Lawrence Nathan Tumey, Ph.D.	X
2002	*Curriculum vitae* of Lawrence Nathan Tumey, Ph.D.	X
2003	Maeda, H., et al., *Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect*, European Journal of Pharmaceutics and Biopharmaceutics (2009) 71:3, 409-419.	X
2004	Adair, J.R., et al., *Antibody–Drug Conjugates – A Perfect Synergy*, Expert Opinion on Biological Therapy (2012) 12:9, 1191-1206	X
2005	Kovtun, Y.V., et al., *Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance*, Cancer Research (2010) 70 (6): 2528–2537.	X
2006	Goldmacher, V., et al., *Antibody–Drug Conjugates: Using Monoclonal Antibodies For Delivery Of Cytotoxic Payloads To Cancer Cells*, Therapeutic Delivery (2011) 2:3, 397-416.	X
2007	Ducry, L., et al., *Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies*, Bioconjugate Chemistry (2010) 21:1, 5–13.	X
2008	Carter P.J., Senter P.D., *Antibody-Drug Conjugates for Cancer Therapy*, Cancer Journal (2008) 14:3, 154-169.	X
2009	Daugherty, A.L., et al., *Formulation and Delivery Issues for Monoclonal Antibody Therapeutics*, Advanced Drug Delivery Reviews (2006) 58:5-6, 686-706.	X

No.	Exhibit Description	Previously submitted
2010	Pappanaicken, R.K., et al., *Evaluation of Ketone-Oxime Method for Delivering Therapeutic On-Demand Cleavable Immunoconjugates*, Bioconjugate Chemistry (2008) 19:6, 1313-1318.	X
2011	Jeffrey, S.C., et al., *Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents*, ACS Medicinal Chemistry Letters (2010) 1, 277-80.	X
2012	Mather, B., et al., *Michael Addition Reactions in Macromolecular Design for Emerging Technologies*, Progress in Polymer Science (2006), 31:5, 487-531.	X
2013	Lopez-Jaramillo, F., et al., *Vinyl Sulfone: A Multi-Purpose Function in Proteomics*, Integrative Proteomics InTech (2012) 16:301-326.	X
2014	Acchione, M., et al., *Impact of Linker and Conjugation Chemistry on Antigen Binding, Fc Receptor Binding and Thermal Stability of Model Antibody-Drug Conjugates*, mAbs (2012) 4:3, 362-372.	X
2015	Hamblett, K., et al., *Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate*, Clinical Cancer Research (2004) 10:20, 7063-7070.	X
2016	Junutula, J., et al., *Site-specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index*, Nature Biotechnology (2008) 26, 925–932.	X
2017	Casi, G., *Antibody-Drug Conjugates: Basic Concepts, Examples, and Future Perspectives*, Journal of Controlled Release (2012) 161:2, 422-428.	X

No.	Exhibit Description	Previously submitted
2018	Li, L., et al., *Vinyl Sulfone Bifunctional Derivatives of DOTA Allow Sulfhydryl- or Amino-Directed Coupling to Antibodies. Conjugates Retain Immunoreactivity and Have Similar Biodistributions*, Bioconjugate Chemistry (2002) 13:1, 110–115.	X
2019	Ballini, R., et al., *Conjugate Additions of Nitroalkanes to Electron-Poor Alkenes: Recent Results*, Chemical Reviews (2005) 105:3, 933–972.	X
2020	Gallagher, S., et al., *Immunoblotting and Immunodetection*, Current Protocols in Cell Biology (2011) 52:6.2.1-6.2.28.	X
2021	Springer Nature, *Citation Details*, Retrieved May 24, 2023, from https://citations.springernature.com/item?doi=10.1007/BF00493477	X
2022	'682 Patent File History, Non-Final Office Action dated August 15, 2017	X
2023	U.S. Patent No. 5,094,848 (Brixner)	X
2024	'682 Patent File History, Applicant Remarks and Response to Non-Final Office Action dated August 15, 2017	X
2025	Non-Final Office Action dated March 8, 2018	X
2026	WO1997/41897 (Lees)	X
2027	'682 Patent File History, Applicant Remarks and Response to Non-Final Office Action dated March 8, 2018	X
2028	'682 Patent File History, Final Office Action dated July 10, 2018	X
2029	WO2012/145112 (Fishkin)	X

No.	Exhibit Description	Previously submitted
2030	Widdison, W.C., et al., *Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer*, Journal of Medicinal Chemistry (2006) 49:14, 4392-4408.	X
2031	'682 Patent File History, Applicant Remarks and Response to Final Office Action dated July 10, 2018	X
2032	'682 Patent File History, Notice of Allowance	X
2033	'682 Patent Reexamination File History, IDS Form Signed by Examiner on September 10, 2020 Showing List of Considered References	X
2034	WO2009/134976 (Singh '976)	X
2035	Drawing by Dr. Ravi Chari in the November 14, 2024 Deposition	
2036	Drawing by Dr. Ravi Chari in the November 14, 2024 Deposition	
2037	Transcript of the November 14, 2024 Deposition of Dr. Ravi Chari	
2038	Declaration of Lawrence Nathan Tumey, Ph.D., in Support of Patent Owner's Response to Petition for *Inter Partes* Review of U.S. Patent No. 10,131,682	
2039	Declaration of June Ann Munford	
2040	Appendix to Declaration of June Ann Munford	
2041	Springer Nature, *Citation Details*, Retrieved Dec. 4, 2024, from https://citations.springernature.com/item?doi=10.1007/BF00493477	
2042	Dictionary of Science & Technology (2007) at 266.	
2043	Encyclopedia of Chemistry (2005) at 113.	

No.	Exhibit Description	Previously submitted
2044	McGraw-Hill Dictionary of Scientific and Technical Terms (2003) at 865.	
2045	A Dictionary of Science (2010) at 339.	

CERTIFICATE OF SERVICE (37 C.F.R. §§ 42.6(E), 42.105(A))

The undersigned hereby certifies that the foregoing document was served in its entirety on December 6, 2024 upon the following parties via Electronic Mail:

Michael Houston
Joseph Meara
Jolene Fernandes
FOLEY & LARDNER LLP
3000 K Street, NW, Suite 600
Washington, DC 20008
682IPR@foley.com

Date: December 6, 2024

By: */Francis Cerrito/*

Francis Cerrito (Reg. No. 38,100)
QUINN EMANUEL URQUHART & SULLIVAN LLP
51 Madison Avenue, 22nd Floor
New York, NY 10010
Email: nickcerrito@quinnemanuel.com
Tel: (212) 849-7000
Fax: (212) 849-7100

Counsel for Patent Owner
Hangzhou DAC Biotech Co., Ltd.